KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Liabilities from Discontinued Operations (2016 - 2017)

Historic Liabilities from Discontinued Operations for Teva Pharmaceutical Industries (TEVA) over the last 5 years, with Q4 2025 value amounting to $354.0 million.

  • Teva Pharmaceutical Industries' Liabilities from Discontinued Operations fell 4928.37% to $354.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $354.0 million, marking a year-over-year decrease of 4928.37%. This contributed to the annual value of $354.0 million for FY2025, which is 4928.37% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Liabilities from Discontinued Operations of $354.0 million as of Q4 2025, which was down 4928.37% from $698.0 million recorded in Q4 2024.
  • In the past 5 years, Teva Pharmaceutical Industries' Liabilities from Discontinued Operations ranged from a high of $698.0 million in Q4 2024 and a low of $354.0 million during Q4 2025